Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03133286
Other study ID # DXT-RADTOX-AC03
Secondary ID HHSN261201600051
Status Recruiting
Phase
First received
Last updated
Start date April 6, 2017
Est. completion date September 6, 2019

Study information

Verified date February 2019
Source DxTerity Diagnostics
Contact Kristen Warren
Phone 310-537-7857
Email kwarren@dxterity.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Collect blood samples and associated clinical data prior to, during, and post radiation treatment.


Description:

In order to further refine and independently validate the performance of DxTerity's test developed during the previous pilot study, the study will collect pre-, during, and post-irradiation blood samples and associated clinical and self-reported information from up to five hundred (500) subjects for analysis. Patients with a diagnosis of primary gastrointestinal (GI), genitourinary (GU), or gynecological (GYN) cancer requiring radiation treatment to the primary disease site will be included in the study. Combining chemotherapy is allowed.

Blood samples for this study will be collected from cancer patients scheduled to undergo radiation therapy prior to, during, and after treatment. Approximately 150μL of blood per time point will be obtained via fingerstick remotely, from the participant's home or doctor's office; participation in this study will not affect any aspect of patient treatment. Samples will be collected using DxTerity's proprietary DxCollect® MCD Fingerstick Kit (MCD).


Recruitment information / eligibility

Status Recruiting
Enrollment 500
Est. completion date September 6, 2019
Est. primary completion date September 6, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Male and female patients age 18 or older

2. Have a permanent address in the United States for the duration of the study

3. Have an email address and access to the internet for the duration of the study

4. Diagnosed with a primary gastrointestinal (GI), genitourinary (GU), or gynecological (GYN) cancer

5. Planned radiation therapy to the abdominal/pelvic area as part of clinical care

6. Able to provide informed consent

Exclusion Criteria:

1. Receipt of radiation within three (3) months to abdominal/pelvic area prior to scheduled start of Radiation Treatment

Study Design


Related Conditions & MeSH terms

  • Anus Neoplasms
  • Cancer
  • Cancer of Anus
  • Cancer of Bladder
  • Cancer of Cervix
  • Cancer of Colon
  • Cancer of Esophagus
  • Cancer of Gallbladder
  • Cancer of Kidney
  • Cancer of Kidney and Renal Pelvis
  • Cancer of Liver
  • Cancer of Ovary
  • Cancer of Pancreas
  • Cancer of Prostate
  • Cancer of Rectum
  • Cancer of Stomach
  • Cancer of Testis
  • Cancer of Uterus
  • Cancer of Uterus and Cervix
  • Carcinoma, Renal Cell
  • Colonic Neoplasms
  • Esophageal Neoplasms
  • Gallbladder Neoplasms
  • Kidney Neoplasms
  • Liver Neoplasms
  • Ovarian Neoplasms
  • Pancreatic Neoplasms
  • Prostatic Neoplasms
  • Radiation Therapy
  • Rectal Neoplasms
  • Stomach Neoplasms
  • Testicular Neoplasms
  • Urinary Bladder Neoplasms
  • Uterine Cervical Neoplasms
  • Uterine Neoplasms

Locations

Country Name City State
United States 21st Century Oncology Bradenton Florida
United States DxTerity Diagnostics Compton California
United States 21st Century Oncology Fort Myers Florida
United States 21st Century Oncology Plantation Florida

Sponsors (2)

Lead Sponsor Collaborator
DxTerity Diagnostics National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Obtain pre- and post-irradiation participant-collect blood samples Obtain pre-irradiation participant-collected blood samples as well subsequent 3 participant-collected blood samples and associated clinical data from cancer patients undergoing abdominal/pelvic radiation therapy as part of clinical care. 1.5 years
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients